1-adamantyl glycidyl ether | 130187-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: 1-adamantyl glycidyl ether
• 英文别名: 1-adamantylglycidyl ether；2-[(1-Adamantyloxy)methyl]oxirane；2-(1-adamantyloxymethyl)oxirane
• CAS: 130187-71-2
• 化学式: C₁₃H₂₀O₂
• 分子量: 208.301
• InChiKey: SOIAGOLKGAHWEU-UHFFFAOYSA-N

物化性质

• 沸点：
  130-135 °C(Press: 10 Torr)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-adamantyl glycidyl ether 在 硫脲 作用下， 以 异丙醇 为溶剂， 反应 0.5h， 以93%的产率得到1-adamantyl thioglycidyl ether
  参考文献：
  名称：

  Synthesis and antiviral activity of adamantyloxiranes and their derivatives

  摘要：

  DOI：

  10.1007/bf00766248
• 作为产物：
  描述：

  1-adamantyl 3-chloro-2-hydroxypropyl ether 在 sodium hydroxide 作用下， 以 异丙醇 为溶剂， 反应 1.0h， 生成 1-adamantyl glycidyl ether
  参考文献：
  名称：

  Shiryaev, A. K.; Pavskii, V. I.; Moiseev, I. K., Journal of Organic Chemistry USSR (English Translation), 1991, vol. 27, # 6.2, p. 1089 - 1092

  摘要：

  DOI：

文献信息

• Method of using calcilytic compounds
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US06022894A1

  公开（公告）日：2000-02-08

  The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

  本发明涉及钙受体拮抗剂化合物。"钙受体拮抗剂化合物"指的是能够抑制钙受体活性的化合物。还描述了利用钙受体拮抗剂化合物来抑制钙受体活性和/或在患者中达到有益效果的方法；以及可用于获取额外钙受体拮抗剂化合物的技术。
• Calcilytic compounds
  申请人：Del Mar G. Eric

  公开号：US20050032850A1

  公开（公告）日：2005-02-10

  The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

  本发明涉及钙解离化合物。 "钙解离化合物"是指能够抑制钙受体活性的化合物。还描述了使用钙解离化合物来抑制钙受体活性和/或在患者中获得有益效果的方法；以及可用于获得其他钙解离化合物的技术。
• Curable polycyclic compounds and process for the production thereof
  申请人：Takenaka Junji

  公开号：US20060252911A1

  公开（公告）日：2006-11-09

  The present invention discloses a curable polycyclic compound represented by the following formula (1): wherein A is a di- to hexa-valent group derived from a polycyclic hydrocarbon compound; R 1 is an alkyl group of 1 to 4 carbon atoms, a perfluoroalkyl group of 1 to 4 carbon atoms, or a fluorine atom; n is an integer of 0 to 2; m is an integer of 2 to 4; and Y is a group represented by the following formula (2) or (3): (wherein R 2 , R 3 , R 5 and R 6 are each independently a hydrogen atom, a fluorine atom or an alkyl group of 1 to 4 carbon atoms; R 4 is a methyl group or an ethyl group; and p and q are each independently an integer of 0 to 4)}.

  本发明披露了一种可固化的多环化合物，其表示如下式（1）：其中A是从多环碳氢化合物衍生的二至六价基团；R1是1至4个碳原子的烷基、1至4个碳原子的全氟烷基或氟原子；n是0至2的整数；m是2至4的整数；Y是以下式（2）或（3）所表示的基团：（其中R2，R3，R5和R6各自独立地是氢原子、氟原子或1至4个碳原子的烷基；R4是甲基或乙基基团；p和q各自独立地是0至4的整数）。
• CALCILYTIC COMPOUNDS
  申请人：Del Mar Eric G.

  公开号：US20070249702A1

  公开（公告）日：2007-10-25

  The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

  本发明涉及钙解离化合物。 “钙解离化合物”是指能够抑制钙受体活性的化合物。同时，本发明还描述了使用钙解离化合物来抑制钙受体活性和/或在患者中获得有益效果的方法；以及可用于获得其他钙解离化合物的技术。
• Novel Carvedilol Analogues That Suppress Store-Overload-Induced Ca²⁺ Release
  作者：Chris D. Smith、Aixia Wang、Kannan Vembaiyan、Jingqun Zhang、Cuihong Xie、Qiang Zhou、Guogen Wu、S. R. Wayne Chen、Thomas G. Back

  DOI：10.1021/jm401090a

  日期：2013.11.14

  Carvedilol is a uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure. This activity is in part because of its ability to inhibit store-overload-induced calcium release (SOICR) through the RyR2 channel. We describe the synthesis, characterization, and bioassay of ca. 100 compounds based on the carvedilol motif to identify features that correlate with and optimize SOICR inhibition. A single-cell bioassay was employed on the basis of the RyR2-R4496C mutant HEK-293 cell line in which calcium release from the endoplasmic reticulum through the defective channel was measured. IC50 values for SOICR inhibition were thus obtained. The compounds investigated contained modifications to the three principal subunits of carvedilol, including the carbazole and catechol moieties, as well as the linker chain containing the beta-amino alcohol functionality. The SAR results indicate that significant alterations are tolerated in each of the three subunits.